Global PARP Inhibitors Drug Therapy Market Forecast 2028

Global PARP Inhibitor Market Expected To Surpass USD 6 Billion By 2028 Says Kuick Research

 

Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 Report Highlights:

 

• Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
• Commercially Available PARP inhibitors: > 5 Drugs
• Comprehensive Clinical Insight On More Than 35 PARP Drug In Clinical Trials
• Global PARP Clinical Trials Insight by Company, Country, Indication & Phase
• Market Indicators Till 2028
• Approved Drugs Dosage, Sales, Patent, Price Insight
• Approved Drugs Sales Forecast Till 2028
• Global & Regional Market Analysis
• Regional Analysis Based On Drug Approvals:  US, Europe, China & Japan

 

Download Report:  https://www.kuickresearch.com/report-parp-inhibitors-market

 

Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. This helps to restore DNA when it is damaged by many factors such as exposure to UV radiation, some anti-cancer drugs and others. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in the DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency of other DNA repair pathways. Attributed to this, these inhibitors are extensively being used for the treatment of various types of cancers such as ovarian and breast cancer.

 

To date, 4 PARP inhibitors have been approved by US FDA and EMA including Olaparib, Niraparib, Rucaparib, and Talazoparib. Apart from this, regulatory bodies have also granted orphan drug designation to these drugs. For instance, FDA granted orphan drug designation to veliparib for the treatment of advanced squamous non–small cell lung cancer, according to the drug’s manufacturer. Veliparib developed by AbbVie is a potential PARP inhibitor present in late stage clinical trial and is expected to enter the market in coming years. The designation allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials and upon regulatory approval 7 years of market exclusivity.

 

The combinational therapy is expected to dominate the market in the forthcoming years which is mainly due to their ability to enhance the efficacy in the management of cancer. Recent study evaluated triplet combination of the PARP inhibitor olaparib (Lynparza), metronomic cyclophosphamide, and metformin in endometrial carcinoma. The initial results have demonstrated that the combination accheived non progression rate and significantly enhanced the overall survival rates in patients. In addition to this, Janssen Pharmaceutical is also evaluating niraparib combination with abiraterone acetate, in the form of a dual action tablet (DAT)* plus prednisolone, for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR)+ gene alterations.

 

Regionally, US is currently having the maximum share in the global market which is mainly due to presence of large number of clinical trials. Several other factors including increase geriatric population, high acceptance to novel therapies and the rising initiatives by government sector to propel the research and development sector also acts as driver to the regional marker. Moreover, the presence of major key players also boosts the growth of market in this region. Apart from this, China will also emerge as prominent market in forthcoming years due to presence of several domestic PARP inhibitors and large population prone to cancer.

 

As per our report findings, the global PARP inhibitor market is expected to surpass US$ 6 Billion by 2028. The growth factors of the global market include the increase in cancer incidences, rising demand for better treatment options, and increasing focus on targeted therapies. Other drivers include the growing number of approvals for novel drugs, technological advancements in drug delivery systems, and increasing investment by pharmaceutical companies in research and development activities. However, patent expiries of key products and stringent regulatory requirements are expected to hamper market growth during the forecast period.

 

Our report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, pricing, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

 

Contact:

 

Neeraj Chawla

Kuick research

Research Head

+91-981410366

neeraj@kuickresearch.com

https://www.kuickresearch.com